Top 10 Medical VC (Venture Capital) Funds in Iceland in May 2026

Portfolio highlights

• HorseDay — HorseDay is a mobile application to track horse activities.
• Spectaflow — Spectaflow is a SaaS solution for accommodations businesses focused on improving housekeeping and maintenance workflows
• PayAnalytics — PayAnalytics, a leading pay equity and workforce analytics solution, aids companies in closing pay gaps and fostering workplace equity. Ensure compliance with pay transparency regulations, assess wage disparities, and analyze workforce demographics conveniently.

Portfolio highlights

• Numan — Convenient care, tailored to you. Offering treatments for weight loss, diagnostics, erectile dysfunction, hair loss, and more.
• Nord Security — Nord Security is the leader in the field of online privacy and security. Our security tools have earned praise from respected experts and tech outlets.
• Steel City Interactive — Steel City Interactive develops gaming.

Portfolio highlights

• PLAIO — PLAIO is a web-based SaaS platform intended to help generic pharmaceutical companies to digitize their demand, manufacturing, and purchase planning.PLAIO offers features like visual and capacity planning, advanced constraint/overhead calculations.
• Moombix — Join us for the launch of our advanced learning platform for online music lessons
• Treble — We develop next generation sound simulation and spatial audio technology for digital twins and virtual worlds.

Portfolio highlights

• Chimerix — Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA(dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.
• Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
• TScan Therapeutics — Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien velit, aliquet eget commodo nec, auctor a sapien. Nam eu neque vulputate diam rhoncus faucibus. Curabitur quis varius libero.

Portfolio highlights

• Polka Pop — Polka Pop is India's first brand to serve naturally flavored sparkling water with zero calories and no added sugar. Supporting a sustainable lifestyle choice, this healthy drink is available in four flavors, i.e. lemon-lime, orange, peach, and cranberry. The fizz makes this the best mix for cocktails and mocktails.
• EpiEndo Pharmaceuticals — Welcome to EpiEndo Pharma | Developing epithelial barrier enhancing drugs to treat chronic respiratory diseases

Portfolio highlights

• KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
• Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
• Vitara Biomedical — Vitara is a biomedical technology company reinventing the standard of care for extremely premature newborns

Portfolio highlights

• 3Z Pharmaceuticals — 3Z Pharmaceuticals provides research services intended to provide drug development services. It offers drug screening on sleep and epilepsy assays that helps in the development of drugs used to treat neurological disorders, enabling patients to get multiple drug efficacy and toxicity assays.Karl Karlsson and Haraldur Thorsteinsson founded 3ZPharmaceuticals in 2008. It based their company on their research on the sleeping patterns of the zebrafish at the Reykjavik University Neurolab in 2006.

Portfolio highlights

• PLAIO — PLAIO is a web-based SaaS platform intended to help generic pharmaceutical companies to digitize their demand, manufacturing, and purchase planning.PLAIO offers features like visual and capacity planning, advanced constraint/overhead calculations.
• EpiEndo Pharmaceuticals — Welcome to EpiEndo Pharma | Developing epithelial barrier enhancing drugs to treat chronic respiratory diseases

Portfolio highlights

• DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
• Sidekick Health — Our mission is to develop and deliver effective personalized digital therapeutics that prevent suffering and add millions of quality life years to people around the world. Our multi-chronic digital care platform allows us to scale the production of clinical treatments across major chronic diseases.
• INBRAIN Neuroelectronics — We are scientists, doctors, techies and humanity lovers, with the mission of building neuroelectronic interfaces to cure brain disorders.

Portfolio highlights

• AviLabs — AviLabs specializes in software development in aviation.
• Laki Power — We supply power grid operators with advanced high-voltage line monitoring stations that enable them to optimise performance, safety and cost.
• Porcelain Fortress — Porcelain Fortress was founded by a small band of romantics in the summer of 2016 in Reykjavik, Iceland.